Although a recent paper has demonstrated that Dmab may induce a short-term positive effect on insulin resistance in postmenopausal women and women with breast cancer treated with an aromatase inhibitor, data from post hoc analyses on the FREEDOM trial did not confirm a positive action of Dmab on glycemic outcomes. The gene discussed is CYP19A1; the disease is breast cancer.